By Stephen Nakrosis
Shares of Cumberland Pharmaceuticals were trading higher in the after-hours market after the company said the Food and Drug Administration approved a supplemental new drug application for liver drug Acetadote.
After the bell Monday, the company's shares had risen 56%, trading at $1.93. Volume in the after-hours market surpassed 4.4 million shares.
The stock finished the regular session with a gain of less than 1%, closing at $1.24.
Acetadote is an intravenous formulation indicated to prevent or lessen liver injury after ingestion of potentially toxic quantities of acetaminophen, according to the company.
Each year, thousands of individuals in the U.S. experience accidental or intentional acetaminophen poisoning, leading to serious liver damage, the company said.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
December 09, 2024 17:36 ET (22:36 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.